Published in Br J Cancer on January 23, 2014
The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol (2015) 1.82
Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut (2014) 1.14
Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer. Genome Biol (2014) 1.05
Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer. Oncotarget (2015) 0.90
Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer. Cancer Sci (2014) 0.87
Targeted therapies in gastric cancer and future perspectives. World J Gastroenterol (2016) 0.86
Patient-Derived Gastric Carcinoma Xenograft Mouse Models Faithfully Represent Human Tumor Molecular Diversity. PLoS One (2015) 0.85
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). Int J Mol Med (2016) 0.85
Sprouty2 correlates with favorable prognosis of gastric adenocarcinoma via suppressing FGFR2-induced ERK phosphorylation and cancer progression. Oncotarget (2017) 0.84
A long non-coding RNA signature to improve prognosis prediction of gastric cancer. Mol Cancer (2016) 0.82
Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy. Genes Cancer (2016) 0.81
Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis. PLoS One (2015) 0.80
Global chemotherapy development for gastric cancer. Gastric Cancer (2016) 0.79
Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma. Oncotarget (2016) 0.79
Personalized medicine in gastric cancer: Where are we and where are we going? World J Gastroenterol (2016) 0.79
Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma. Oncotarget (2016) 0.77
Therapeutic targeting of fibroblast growth factor receptors in gastric cancer. Gastroenterol Res Pract (2015) 0.77
FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. Mod Pathol (2016) 0.76
Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers. J Gastrointest Oncol (2016) 0.75
Novel Targeted Therapies for Esophagogastric Cancer. Surg Oncol Clin N Am (2017) 0.75
Different clinical significance of FGFR1-4 expression between diffuse-type and intestinal-type gastric cancer. World J Surg Oncol (2017) 0.75
Adjuvant therapy for gastric cancer: what have we learned since INT0116? World J Gastroenterol (2015) 0.75
Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation. Oncotarget (2016) 0.75
Companion diagnostics for the targeted therapy of gastric cancer. World J Gastroenterol (2015) 0.75
PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC). Oncotarget (2017) 0.75
Expression and clinical significance of fibroblast growth factor 1 in gastric adenocarcinoma. Onco Targets Ther (2015) 0.75
Identifying fusion transcripts using next generation sequencing. Wiley Interdiscip Rev RNA (2016) 0.75
Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways. BMC Cancer (2017) 0.75
Translating genomic profiling to gastrointestinal cancer treatment. Future Oncol (2017) 0.75
Genomic and epigenomic heterogeneity in molecular subtypes of gastric cancer. World J Gastroenterol (2016) 0.75
Targeted therapies for gastric cancer: failures and hopes from clinical trials. Oncotarget (2017) 0.75
Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model. Transl Oncol (2017) 0.75
A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer. Target Oncol (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand (1965) 22.65
Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev (2005) 9.62
Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer (2010) 8.55
Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res (2005) 7.66
A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet (2005) 6.70
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev (2005) 3.91
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res (2010) 3.89
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol (2013) 3.53
Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res (2001) 2.77
AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res (2012) 2.60
Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res (2009) 2.49
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol (2012) 2.45
Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res (2012) 2.26
Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res (2012) 2.16
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene (2010) 2.11
FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov (2012) 1.83
Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res (2012) 1.74
Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest (1998) 1.68
Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol (2012) 1.65
Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin Cancer Res (2012) 1.53
FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res (2013) 1.51
Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut (2006) 1.45
Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol (2012) 1.42
Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. Diagn Pathol (2006) 1.37
FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer (2012) 1.34
Actions and mode of actions of FGF19 subfamily members. Endocr J (2007) 1.33
FGF signaling network in the gastrointestinal tract (review). Int J Oncol (2006) 1.32
Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res (1996) 1.19
GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res (2010) 1.18
Isolation of an amplified DNA sequence in stomach cancer. Jpn J Cancer Res (1990) 1.18
Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. Hum Pathol (2012) 1.08
Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts. Clin Cancer Res (2010) 1.08
Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer. J Clin Gastroenterol (2012) 1.08
Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard? Curr Treat Options Oncol (2011) 1.02
Quantitative and Sensitive Detection of Cancer Genome Amplifications from Formalin Fixed Paraffin Embedded Tumors with Droplet Digital PCR. Transl Med (Sunnyvale) (2012) 0.93
Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics. Expert Rev Anticancer Ther (2010) 0.91
Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer (2013) 0.87
Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2008) 0.83
Status of tissue expression and serum levels of HER2 in gastric cancer patients in Japan. Hepatogastroenterology (2013) 0.82
DNA amplification in human gastric carcinomas. Cancer Genet Cytogenet (1993) 0.78